Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Exact Sciences released data from a study of its ... Exact, which makes the Cologuard fecal immunochemical test (FIT) test for colorectal cancer, said it is completing additional studies to ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results ...

Exact Sciences' management envisions blood-based testing as a viable alternative for those who decline both colonoscopy and Cologuard tests. Moreover, it is seen as a potential stepping stone for ...

Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.